Danuglipron — references and citing documents
The full reference list for this monograph, and every Institute document that draws on it.
§10References
Every reference the monograph relies on is listed below in order of first citation across the document. Identifiers are reproduced only where the Institute holds them; where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed one.
This monograph cites 3 sources[1,2,3].
Table 9. Bibliographic records for the sources cited by this monograph. Each links to its record page, which lists every Institute document citing it.
| # | Title | Source | Year |
|---|---|---|---|
| 1 | Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic… | JAMA Network Open | 2023 |
| 2 | Mechanisms of action and therapeutic application of glucagon-like peptide-1 | Cell Metabolism | 2018 |
| 3 | ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit… | ICH Harmonised Guideline | 2023 |
§11Related Institute documents
Table 10. Institute documents that draw on, or are drawn on by, this monograph.
| Series | Count | Documents |
|---|---|---|
| Trial abstracts | 8 | DANU-PH2B-OBESITY · DANU-PH2B-T2D · DANU-PH2B-OBESITY-QOL · DANU-PH2B-T2D-BODY-COMP · DANU-PH2B-OBESITY-REGIONAL-CN · DANU-PH2B-T2D-REGIONAL-JP · DANU-PH2B-OBESITY-REGIONAL-JP · DANU-PH2B-T2D-REGIONAL-CN |
| Evidence syntheses | 3 | Gastrointestinal adverse events with incretin receptor… · Oral compared with injectable presentations of… · Discontinued development programmes as evidence |
| Comment periods | 1 | Draft monograph: danuglipron |
| Indication assessments | 2 | Type 2 diabetes · Obesity |
Numbered reference list
References are numbered in order of first citation in this document. Each superscript in the text links to its entry below.
- Saxena AR, Frias JP, Brown LS, Gorman DN, Vasas S, Tsamandouras N, Birnbaum MJ. Efficacy and safety of oral small molecule glucagon-like peptide 1 receptor agonist danuglipron for glycemic control among patients with type 2 diabetes: a randomized clinical trial. JAMA Network Open 2023;6(5):e2314493. doi:10.1001/jamanetworkopen.2023.14493 · PMID 37237090
- Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metabolism 2018;27(4):740–756. doi:10.1016/j.cmet.2018.03.001 · PMID 29617641
- International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk. ICH Harmonised Guideline 2023;Step 4 version. identifier not held by the Institute
Identifiers are reproduced only where the Institute holds them. Where a digital object identifier or PubMed identifier is not shown, the Institute has recorded the journal and year and has not constructed an identifier.